INDEE, INC

Medtech · Private

Microfluidic device for CD3+ T cell enrichment and capture from whole blood for cell therapy manufacturing

Grants
$906K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
3 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Integrating microfluidic vortex shedding-mediated gene delivery into the development and manufacture pipelines of adoptive cellular immunotherapies$300,000
Federal grantDepartment of Health and Human Services · Phase I · Rapid, single-step precision engineering and pre-clinical evaluation of chimeric antigen receptor Regulatory T cells for Type 1 diabetes$309,636
Federal grantDepartment of Health and Human Services · Phase I · High efficiency microfluidic device for large scale engineered cell therapy manufacturing$295,924
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
649HYPERSOUND MEDICAL, INC.——
650KANONA, INC.——
651RIGHTAIR, LLC——
652INDEE, INC——
653ATMAN THERAPEUTICS CO.——
654Smart Human Dynamics, Inc.——
655REDUX HOLDINGS INC—$250K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 3

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.